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Abstract

Human glyoxalase II (Glx2) was overexpressed in rich medium and in minimal medium containing zinc, iron, or
cobalt, and the resulting Glx2 analogues were characterized using metal analyses, steady-state and pre-steadystate kinetics, and NMR and EPR spectroscopies to determine the nature of the metal center in the enzyme.
Recombinant human Glx2 tightly binds nearly 1 equiv each of Zn(II) and Fe. In contrast to previous reports, this
study demonstrates that an analogue containing 2 equiv of Zn(II) cannot be prepared. EPR studies suggest that
most of the iron in recombinant Glx2 is Fe(II). NMR studies show that Fe(II) binds to the consensus Zn2 site in
Glx2 and that this site can also bind Co(II) and Ni(II), suggesting that Zn(II) binds to the consensus Zn1 site. The
NMR studies also reveal the presence of a dinuclear Co(II) center in Co(II)-substituted Glx2. Steady-state and
pre-steady-state kinetic studies show that Glx2 containing only 1 equiv of Zn(II) is catalytically active and that
the metal ion in the consensus Zn2 site has little effect on catalytic activity. Taken together, these studies
suggest that Glx2 contains a Fe(II)Zn(II) center in vivo but that the catalytic activity is due to Zn(II) in the Zn1 site.
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The glyoxalase system consists of two enzymes, lactoylglutathione lyase (glyoxalase I, Glx1) and
hydroxyacylglutathione hydrolase (glyoxalase II, Glx2) (1-3). Glx1 is capable of forming S-(2hydroxyacyl)glutathione (SLG),1 which is made from the thiohemiacetal produced from a spontaneous reaction
of methylglyoxal and glutathione. SLG (and other related glutathione thiolesters) is then hydrolyzed by Glx2 to
form d-lactate and glutathione. Glyoxalase I can utilize a number of α-ketoaldehydes; however, the primary
physiological substrate of the system is thought to be methylglyoxal (MG), a cytotoxic and mutagenic compound
that is formed primarily as a byproduct of carbohydrate and lipid metabolism and from triosephosphates (2, 46). SLG is also cytotoxic because of its ability to inhibit DNA synthesis (2, 7). While SLG can also be metabolized
by γ-glutamyltransferase and dipeptidase, these processes generate N-d-lactoylcysteine, which also inhibits
nucleotide synthesis (7). Therefore, the glyoxalase system, which depletes MG and SLG, plays a critical role in
cellular detoxification (1, 8).
Abbreviations: EDTA, ethylenediaminetetraacetic acid; FPLC, fast performance liquid chromatography; Glx2Comin, recombinant human glyoxalase II overexpressed in minimal medium containing Co(II); Glx2-Comin+Zn(II),

recombinant human glyoxalase II overexpressed in minimal medium containing Co(II) to which was added 1
equiv of Zn(II); Glx2-Femin+Zn(II), recombinant human glyoxalase II overexpressed in minimal medium containing
Fe and Zn(II); Glx2-LB, recombinant human glyoxalase II overexpressed in LB medium; Glx2-LB+1.5Zn+1.5Fe,
recombinant human glyoxalase II overexpressed in LB medium which was incubated with 1.5 equiv of Zn(II) and
Fe(II) and dialyzed; Glx2-Znmin, recombinant human glyoxalase II overexpressed in minimal medium containing
Zn(II); Glx2-Znmin+Ni(II), recombinant human glyoxalase II overexpressed in minimal medium containing Zn(II) to
which was added 1 equiv of Ni(II); Glx2-Znmin+3equivFe(II), recombinant human glyoxalase II overexpressed in
minimal medium containing Zn(II) which was incubated with 3 equiv of Fe(II) and dialyzed; Glx2Znmin+3equivZn(II), recombinant human glyoxalase II overexpressed in minimal medium containing Zn(II) which
was incubated with 3 equiv of Zn(II) and dialyzed; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid;
ICP-AES, inductively coupled plasma with atomic emission spectroscopy detection; IPTG, isopropyl β-dthiogalactopyranoside; LB, Luria-Bertani; MG, methylglyoxal; MOPS, 3-morpholinopropanesulfonic acid; PMSF,
phenylmethanesulfonyl fluoride; SDS−PAGE, sodium dodecyl sulfate−polyacrylamide gel electrophoresis; SLG, S(2-hydroxyacyl)glutathione.
Because of its role in cellular detoxification, the glyoxalase system has received considerable attention as a
possible antitumor and antiparasitic target in animal systems (1, 9-18). Increased levels of Glx1 and Glx2 mRNA
and protein have been detected in tumor cells, such as in breast carcinoma cells, and glyoxalase inhibitors have
been shown to inhibit the growth of tumor cells in vitro (19). Therefore, it has been proposed that the targeted
inhibition of glyoxalase enzymes can be a viable anticancer strategy (5, 11, 13, 18, 20-26). Plasmodium
falciparum and the protozoan Leishmania exhibit high rates of methylglyoxal formation and increased levels of
Glx1 activity (27, 28). In Leishmania infantum, trypanothione is used instead of glutathione, and a crystal
structure of L. infantum Glx2 bound to S-d-lactoyltrypanothione has recently been reported (29).
Alterations in glyoxalase activity have also been associated with several other disease states. Glx1 and Glx2 can
inhibit the formation of hyperglycemia-induced advanced glycation end products, suggesting that these
enzymes may have a role in diabetic microangiopathy (30). Glyoxalase enzymes may also play a role in the
pathogenesis of Alzheimer’s disease (31, 32). Finally, Glx2 has been identified as a target of p63 and p73 and
suggested to be a prosurvival factor of the p53 family of transcription factors (33).
Glx2 has been purified and biochemically characterized from many sources, such as plants, mammalian
liver, Salmonella, and Escherichia coli(34-39). Cameron et al. reported the crystal structure of human Glx2 (40),
which defined an overall structure and showed the presence of a dinuclear zinc active site similar to those in the
enzymes of the metallo-β-lactamase superfamily (41, 42). The structure had two domains: a four-layered α
sandwich similar to that seen in metallo-β-lactamases and a predominately α-helical domain (40). As with other
metallo-β-lactamase family enzymes, the metal ion in the Zn1 site was coordinated by His54, His56, His110,
bridging Asp134, and a bridging hydroxide. The metal ion in the Zn2 site was coordinated by His59, His173,
Asp58, the bridging Asp134, the bridging hydroxide, and a terminally bound solvent molecule (Figure 1).
Although the protein used for crystallography contained ∼1.5 mol of zinc and 0.7 mol of iron per mole of
protein, the authors concluded that human Glx2 contains a dinuclear Zn(II) active site. The issue of iron binding
was not considered, but this omission raises questions concerning the actual metal binding preference of human
Glx2.

Figure 1. Proposed active site of human Glx2 (40). The small spheres are solvent molecules, and the large
spheres are Zn(II) ions. This figure was rendered using Raswin version 2.7.2.2 (60) and Protein Data Bank
entry 1qh5.
In this paper, we present the results of biochemical and spectroscopic studies of human Glx2. Recombinant
human Glx2 was overexpressed in the presence of different combinations of zinc, iron, and cobalt, and the
resulting enzymes were then purified to homogeneity. Steady-state kinetic studies were used to determine the
catalytic properties of the purified Glx2 analogues. ICP-AES was used to determine the metal content of the
purified enzymes, and nuclear magnetic resonance (NMR) and electron paramagnetic resonance spectroscopies
(EPR) were used to probe the dinuclear metal centers. These biochemical and spectroscopic results provide
detailed structural information about the human Glx2 metal center and insights concerning the structure and
kinetic mechanism of the enzyme that may ultimately be used to design inhibitors with potential therapeutic
value.

Experimental Procedures
Overexpression and Purification of Human Glx2
PCR was conducted on a plasmid, which contains the gene for Glx2 from Homo sapiens, which was kindly
provided by B. Mannervik, using the primers CCTCCATGGTAAAAATCGAACTGGTGC and
GAGTCGACTCGAGCTCTAGATCTTTTTTTTTT that generated NdeI and HindIII restriction sites at the 5′ and 3′ ends
of the glx2 gene. The PCR fragment was subcloned into pET26b using the NdeI and HindIII restriction sites, and
the sequence of the resulting pGlx2/pET26b plasmid was confirmed by DNA sequencing. The pGlx2/pET26b
plasmid was transformed into E. coli BL21(DE3) Rosetta cells, and small scale cultures were used to maximize the
recovery of soluble protein at different temperatures (15, 22, 30, and 37 °C). A large-scale overexpression of
human Glx2 was performed as follows. A 10 mL overnight culture of E. coli BL21(DE3) Rosetta cells containing
pGlx2/pET26b was used to inoculate 1 L of LB (Luria-Bertani) medium containing 25 μg/mL kanamycin and 25
μg/mL chloramphenicol. The cells were allowed to grow at 37 °C with shaking until they reached an optical
density at 600 nm of 0.6−0.8. Protein production was induced by making the cultures 0.5 mM in isopropyl-β-dthiogalactopyranoside (IPTG), and the cells were shaken at 22 °C for 24 h. The cells were collected by
centrifugation (15 min at 7000g), and the cell pellets were stored at −80 °C until further use.
The cell pellet was thawed and resuspended in 15 mL of 10 mM MOPS (pH 6.5) containing 0.1 μM
phenylmethanesulfonyl fluoride (PMSF). The cells were French pressed four times at 16000 psi and centrifuged

for 30 min at 15000g and 4 °C. The supernatant was dialyzed overnight at 4 °C versus 2 L of 10 mM MOPS (pH
6.5). The dialyzed crude protein sample was centrifuged at 15000g and was subjected to FPLC using an SPSepharose column (1.5 cm × 12 cm with a 25 mL bed volume) that was equilibrated with 10 mM MOPS (pH 6.5).
Bound proteins were eluted with a 0 to 500 mM NaCl gradient in 10 mM MOPS (pH 6.5) at a rate of 2 mL/min.
Fractions containing human Glx2 were identified by sodium dodecyl sulfate−polyacrylamide gel electrophoresis
(SDS−PAGE), pooled, and concentrated by using an Amicon ultrafiltration cell equipped with a YM-10
membrane. Enzyme concentrations were determined by measuring the absorbance at 280 nm and using a molar
extinction coefficient of 23080 M−1 cm−1(40).
Human Glx2 was overexpressed in minimum medium consisting of 2.5 g of glucose, 5 g of casamino acids, 5.5 g
of KH2PO4, 10.8 g of K2HPO4, 1 g of ammonium sulfate, and 10 g of NaCl per 1 L of distilled H2O in the presence of
100 μM Zn(II), Fe(II), Mn(II), or Co(II) to evaluate its metal binding preference. The resulting enzyme samples
were purified as described above.

Metal Analyses
The metal content of Glx2 samples was determined using a Varian-Liberty 150 inductively coupled plasma
spectrometer with atomic emission spectroscopy detection (ICP-AES), as described previously (43). Protein
samples were diluted to 10 μM with 10 mM MOPS (pH 6.5) prior to analysis. A calibration curve with four
standards and a correlation coefficient of >0.99 was generated using Fe, Zn(II), Mn, and Co reference solutions.
The following emission wavelengths were chosen to ensure the lowest detection limits possible: Fe, 259.940 nm;
Zn, 213.856 nm; Mn, 257.610 nm; and Co, 238.892 nm.
To further evaluate metal binding to Glx2, a 3-fold molar excess of Fe(NH4)2(SO4)2, Zn(SO4)2, or
Fe(NH4)2(SO4)2 with Zn(SO4)2 was added directly to purified as-isolated human Glx2, and the mixtures were
allowed to incubate on ice for 1 h. Unbound metal ions were removed by 4 × 1 L dialysis steps against 10 mM
MOPS (pH 6.5) at 4 °C (12 h for each step). The metal content of these protein samples was determined using
ICP-AES as described above.

Steady-State Kinetics
Steady-state kinetic parameters (Km and kcat) of human Glx2 were determined using S-d-lactoylglutathione (SLG)
as a substrate. Thioester hydrolysis was monitored at 240 nm over 30 s at 25 °C as previously reported (43). The
concentration of Glx2 analogues was typically 1−10 nM, and substrate concentrations used were 30−600 μM.
The buffer used in the steady-state kinetic studies was 10 mM MOPS (pH 6.5), containing either no added
metals, 100 μM ZnCl2, or 100 μM Fe(NH4)2(SO4)2.

Stopped-Flow Kinetic Studies
Stopped-flow UV−vis studies were conducted on an Applied Photophysics SX.18-MVR stopped-flow
spectrophotometer at 2 °C. The reaction of Glx2 analogues (final concentration of 32.5 μM) and SLG (final
concentration of 60.5 μM) was monitored at 240 nm for 200 ms. Stopped-flow absorbance data were converted
to concentration data using the SLG extinction coefficient (−3100 M−1 cm−1). All reactions were conducted in
triplicate, and reaction rates were determined by fitting the progress curves to a first-order exponential
equation.

Spectroscopic Studies
1

H NMR spectra were recorded on a Bruker Avance 500 spectrometer operating at 500.13 MHz and 298 K, with a
magnetic field of 11.7 T, a recycle delay (AQ) of 41 ms, and a sweep width of 400 ppm. Chemical shifts were
referenced by assigning the H2O signal a value of 4.70 ppm. A modified presaturation pulse sequence (zgpr) was
used to suppress the proton signals originating from solvent and amino acids not coupled to the metal center.

Line broadening of 50 Hz was used for all of the spectra. The protein concentration was ∼1 mM, and 10% D2O
was included in samples for locking.
EPR spectra were recorded using a Bruker E600 EleXsys spectrometer equipped with an Oxford Instruments
ESR900 helium flow cryostat and ITC503 temperature controller, and an ER4116DM cavity operating at 9.63 GHz
in perpendicular mode. Other recording parameters are given in the figure legend. Quantitation of Fe(III) signals
was conducted by double integration of spectra recorded at nonsaturating power (2 mW) at 12 K. A 2 mM Cu(II)EDTA standard in HEPES buffer (pH 7.5) recorded at 60 K and 50 μW was used. Integration limits and correction
factors for S = 1/2 and S = 5/2 signals, where D is assumed to be small compared to temperature, were
employed (44-46). Co(II) signals were quantified by double integration, with reference to a frozen aqueous
reference sample containing 2 mM Co(II), 50 mM imidazole, and 10% by volume glycerol, recorded at 12 K and
0.8 mW. EPR simulations were performed using XSophe (Bruker Biospin), assuming S = 3/2 and |D| ≫ hν.

Results
Overexpression and Purification of Human Glx2
High levels of soluble human Glx2 were produced in E. coli BL21(DE3) Rosetta cells grown in LB medium at 22 °C.
The colorless recombinant protein eluted via SP-Sepharose chromatography at 100 mM NaCl in 10 mM MOPS
(pH 6.5). Approximately 20 mg of purified Glx2 per liter of culture was obtained using this method. Human Glx2,
overexpressed in LB medium (Glx2-LB), was shown to bind 0.4 ± 0.1 equiv of Zn(II) and 0.5 ± 0.1 equiv of Fe
(Table 1). After incubation with 1.5 equiv of Zn(II) and 1.5 equiv of Fe(II), followed by exhaustive dialysis, human
Glx2 (Glx2-LB+1.5Zn+1.5Fe) was shown to bind 1.2 ± 0.1 equiv of Zn(II) and 0.9 ± 0.1 equiv of Fe (Table 1).
Table 1. Metal Content and Steady-State Kinetic Constants for Human Glx2 Analogues
enzyme
Glx2-LB
Glx2-LB+1.5Zn+1.5Fe
Glx2-Znmin
Glx2-Znmin+3equivZn(II)
Glx2-Znmin+3equivFe(II)
Glx2-Znmin in 100 μM Fe buffer
Glx2-Znmin in 100 μM Zn(II) buffer
Glx2-Femin+Zn(II)
Glx2-Comin
Glx2-Comin+1equivZn(II)
Glx2-Znmin+1equivNi
a
Not applicable.
b
None detected.

Zn(II) (equiv)
0.4 ± 0.1
1.2 ± 0.1
1.1 ± 0.2
0.9 ± 0.2
1.0 ± 0.1
N/Aa
N/Aa
0.5 ± 0.2
0.1 ± 0.1
1.0
0.1 ± 0.1

Fe (equiv)
0.5 ± 0.1
0.9 ± 0.1
NDb
NDb
0.7 ± 0.1
N/Aa
N/Aa
0.6 ± 0.2
0.2 ± 0.1
0.2 ± 0.1
0.2 ± 0.1

Co or Mn (equiv)
NDb (Mn)
NDb (Mn)
NDb (Mn)
NDb (Mn)
NDb (Mn)
N/Aa
N/Aa
NDb (Mn)
1.0 ± 0.1 (Co), NDb (Mn)
1.0 ± 0.1 Co
1.0 Ni

kcat (s−1)
570 ± 99
740 ± 40
407 ± 13
262 ± 24
281 ± 28
355 ± 24
384 ± 9
240 ± 5
815 ± 36
565 ± 30
439 ± 6

Km (μM)
660 ± 190
780 ± 68
81 ± 11
53 ± 22
81 ± 30
105 ± 24
109 ± 8
256 ± 19
110 ± 17
65 ± 13
91 ± 9

Metal Binding to Human Glx2
Metal binding to human Glx2 was further evaluated by expressing the enzyme in minimum medium containing
various metal ions, and the metal content of the resulting enzymes was analyzed by ICP-AES (Table 1). Glx2,
overexpressed in the presence of 100 μM ZnCl2 (Glx2-Znmin), bound 1.1 ± 0.2 equiv of Zn(II) and <0.005 equiv of
Fe or Mn. When 3 equiv of Zn(II) was added to this enzyme, followed by exhaustive dialysis, the resulting
enzyme [Glx2-Znmin+3equivZn(II)] was shown to bind 0.9 ± 0.2 equiv of Zn(II) and <0.005 equiv of Fe or Mn.
When 3 equiv of Fe(II) was added to Glx2-Znmin followed by dialysis, the resulting enzyme [Glx2Znmin+3equivFe(II)] was shown to bind 1.0 ± 0.1 equiv of Zn(II) and 0.7 ± 0.1 equiv of Fe.

Overexpression of human Glx2 in minimum medium containing 100 μM Fe(NH4)2(SO4)2 or 100 μM MnCl2 did not
result in appreciable amounts of enzyme at any temperature. However, when 5 μM ZnCl2 was added to the
minimal medium containing Fe(II), human Glx2 was overexpressed, and the purified enzyme [Glx2-Femin+Zn(II) in
Table 1] was found to contain 0.5 ± 0.2 equiv of Zn(II) and 0.6 ± 0.2 equiv of Fe. This result suggests that human
Glx2 needs Zn(II) to be overexpressed and that the enzyme may bind 1 mol each of iron and zinc per mole of
enzyme. We tested this hypothesis by incubating Glx2-LB with 1.5 equiv of Zn(II) and Fe(II), and the resulting
enzyme (Glx2-LB+1.5Zn+1.5Fe) was exhaustively dialyzed. Consistent with our hypothesis, Glx2-LB+1.5Zn+1.5Fe
was shown to bind 1.2 ± 0.1 equiv of Zn(II) and 0.9 ± 0.1 equiv of Fe.
Since none of the human Glx2 samples contained significant amount of Mn, we did not determine the effect of
adding Zn(II) to minimal medium containing Mn(II) on Glx2 overexpression. We did, however, find that human
GLX2 does bind cobalt. When the enzyme was overexpressed in minimal medium containing 100 μM CoCl2, Glx2Comin bound 0.1 ± 0.1 equiv of Zn(II), 0.2 ± 0.1 equiv of Fe, and 1.0 ± 0.1 equiv of Co. Therefore, human Glx2
preferentially binds 1 mol each of Fe and Zn(II) per mole of enzyme and can bind 1 mol of Co, but it does not
bind Mn.

Steady-State Kinetics
Steady-state kinetic studies were performed on the different forms of human Glx2 to evaluate the effect of
different metal ions on the catalytic activity of the enzyme. Glx2-LB, which contained 0.4 ± 0.1 equiv of Zn(II) and
0.5 ± 0.1 equiv of Fe, exhibited a kcat of 570 ± 99 s−1 and a Km of 660 ± 190 μM (Table 1). Interestingly, Glx2LB+1.5Zn+1.5Fe, which contained 1.2 ± 0.1 equiv of Zn(II) and 0.9 ± 0.1 equiv of Fe, exhibited relatively similar
values [kcat of 740 ± 40 s−1 and Km of 780 ± 68 μM (Table 1)]. Glx2-Znmin exhibited a kcat of 407 ± 13 s−1 and a Km of
81 ± 11 μM, while purified Glx2-Znmin, which was incubated with 3 equiv or Zn(II) or Fe(II) to increase the Zn(II) or
Fe(II) content, respectively, exhibited kcat values of 262 ± 24 and 281 ± 28 s−1 and Km values of 53 ± 22 and 81 ±
30 μM, respectively. Inclusion of 100 μM Fe(II) or Zn(II) in the assay buffer for Glx2-Znmin in an attempt to further
load the enzyme with metal did not significantly affect the kinetic constants (Table 1). These results suggest that
human Glx2 requires only 1 equiv of Zn(II) for activity. However, Glx2-Comin was also shown to be active with SLG
(kcat of 815 ± 36 s−1 and Km of 110 ± 17 μM). The direct addition of 1 equiv of Co(II) to Glx2-Znmin or Glx2Comin resulted in the formation of a yellow precipitate, most likely due to oxidation of Co(II) to Co(III).

Stopped-Flow Kinetic Studies
To further probe the kinetic behavior of the different human Glx2 analogues, stopped-flow kinetic studies were
conducted in which the disappearance of substrate SLG was monitored over time (Figure 2). Each reaction
mixture contained 33 μM SLG and 60 μM Glx2 analogue. Glx2-LB, which contained 0.4 equiv of Zn(II) and 0.5
equiv of Fe, exhibited a rate of 30 ± 1 s−1. Glx2-Znmin, Glx2-Znmin+3equivFe(II), Glx2-Znmin+3equivZn(II), and Glx2LB+1.5Zn+1.5Fe analogues exhibited essentially the same rate of 49 ± 3 s−1. The Glx2-Femin+Zn(II) analogue,
which contains 0.5 and 0.6 equiv of Zn(II) and Fe, respectively, exhibited the slowest rate (15 ± 1 s−1). On the
other hand, Glx2-Comin, which contains 0.1 equiv of Zn(II), 0.2 equiv of Fe, and 1.0 equiv of Co, exhibited the
fastest rate (139 ± 2 s−1).

Figure 2. Stopped-flow kinetic studies of the reaction of human Glx2 analogues with SLG at 2 °C. The
concentration of Glx2 analogues was 32.5 μM, and the concentration for SLG was 60.5 μM. The following
progress curves are shown: (⬡) Glx2-Femin+Zn(II), (◻) Glx2-LB, (●) Glx2-Znmin, (◆) Glx2-Znmin+3equivZn(II), (◇)
Glx2-Znmin+3equivFe(II), (○) Glx2-LB+1.5Zn+1.5Fe, and (△) Glx2-Comin. The progress curves for Glx2-Znmin, Glx2Znmin+3equivZn(II), Glx2-Znmin+3equivFe(II), and Glx2-LB+1.5Zn+1.5Fe were nearly superimposable.

Spectroscopic Studies
1

H NMR spectroscopy was utilized to probe the metal binding sites of human Glx2. A 1H NMR spectrum of Glx2
containing 1.2 ± 0.1 equiv of Zn(II) and 0.9 ± 0.1 equiv of Fe (Glx2-LB+1.5Zn+1.5Fe) showed two solventexchangeable peaks at 47 and 71 ppm (Figure 3A). Given the line widths of these signals and the fact that the
predicted Zn2 site has two histidines while the Zn1 site has three histidines (40), we predict that there is a Fe(II)
bound to the Zn2 site in this sample. Nonetheless, we cannot completely discount the possibility that Fe(II) is
binding to a histidine from each site or the possibility that Fe(II) is binding to the Zn1 site and one of the histidine
NH protons is in fast exchange with solvent.

Figure 3. 1H NMR spectra of human Glx2 analogues in 10 mM MOPS (pH 6.5) containing 10% D2O: (A) Glx2LB+1.5Zn+1.5Fe, (B) Glx2-Comin, (C) Glx2-Comin with 1 equiv of Zn(II) added, and (D) ZnNi-Glx2. The enzyme
concentrations in these samples were ∼1 mM. The asterisks denote peaks that were solvent-exchangeable. The
magnitude of the peak at 42 ppm in the spectrum of Glx2-Comin decreased by half when the sample was
exchanged in 90% D2O.
The 1H NMR spectrum of Glx2 containing 1.0 ± 0.1 equiv of Co(II) (Table 1) exhibited five paramagnetically
shifted resonances (Figure 3B). The peaks at 55, 71, and 87 ppm completely disappear, and the peak at 42 ppm

decreased by helf when the sample was exchanged in 90% D2O. This result indicates that there are at least four
solvent-exchangeable peaks in the Glx2-Comin sample. The peak at 87 ppm (spectrum B in Figure 3) is larger than
the other peaks, suggesting that this peak may be due to two protons both of which are solvent-exchangeable.
The NMR spectrum of Glx2-Comin suggests that Co(II) binds to four or five histidines and, therefore, that Co(II)
binds to both the Zn1 and Zn2 sites in human Glx2.
To probe whether Zn(II) could displace Co(II) from one of the metal binding sites, 1 equiv of Zn(II) was added to
Glx2-Comin to generate Glx2-Comin+1equivZn(II). The resulting analogue exhibited a kcat of 565 ± 30 s−1 and a Km of
65 ± 13 μM, when using SLG as the substrate (Table 1). The NMR spectrum of this analogue exhibited two
solvent-exchangeable peaks at 47 and 71 ppm (Figure 3C), which are the same positions as the solventexchangeable peaks for the Glx2-LB+1.5Zn+1.5Fe sample (Figure 3A). This result suggests that Glx2 preferentially
binds Zn(II) over Co(II) in the Zn1 site, but not in the Zn2 site.
To test whether the Zn2 site can bind other metal ions in addition to Co(II) and Fe(II), we added 1 equiv of Ni(II)
to Glx2-Znmin to generate a ZnNi analogue of human Glx2. Glx2-Znmin with 1 equiv of Ni exhibited a kcat of 439 ± 6
s−1 and a Km of 91 ± 9 μM when using SLG as the substrate (Table 1). A 1H NMR spectrum of ZnNi-Glx2 showed
two relatively sharp, solvent-exchangeable peaks at 57 and 73 ppm (Figure 3D). In agreement with the other
NMR studies, this result suggests that Ni(II) exhibits a preference for binding to the consensus Zn2 site.
UV−vis spectra of Co(II)-containing Glx2 samples were recorded in an effort to obtain information about the
coordination number of Co(II) in these samples (Figure 4). The spectrum of Glx2-Comin exhibited three peaks
between 500 and 600 nm, which we assign to ligand field transitions of high-spin Co(II) and a weaker feature at
410 nm, which we assign to the presence of Co(III) (47). The extinction coefficient of the ligand field transitions
ranged from 28 to 42 M−1 cm−1, which suggests that the Co(II)’s are five- or six-coordinate. The addition of 1
equiv of Zn(II) to the Glx2-Comin sample did not result in a change in the intensities of the ligand field transitions
or the feature assigned to Co(III). This result suggests that both Co(II)’s in Glx2-Comin are five- or six-coordinate.
There was an increase in the magnitude of the 280 nm peak, which resulted in a relatively higher absorption of
the feature at 410 nm, and a slightly higher absorbance of the ligand field transitions at 500 and 550 nm was due
to enzyme precipitation when Zn(II) was added to the sample.

Figure 4. UV−vis spectra of Glx2-Comin and Glx2-Comin+1equivZn(II). The buffer in these samples was 10 mM
MOPS (pH 6.5), and the enzyme concentration was 1.6 mM.
Essentially indistinguishable EPR spectra were observed for both Glx2-LB and Glx2-LB+1.5Zn+1.5Fe and were
dominated by a geff = 4.3 signal due to Fe(III) (Figure 5). Unlike the rich spectra observed from other Glx2 species,
such as Arabidopsis mitochondrial Glx2−5 (34, 48, 49), the S = 5/2 signals from human Glx2 contained no wellresolved features other than the geff = 4.3 line. This result suggests very high strains in the rhombic zero-field

splitting term, E/D, and provides no confirmatory evidence of binding of Fe(III) to human Glx2 in a well-defined
tight binding site. The intensities of the spectra from human Glx2 were equivalent and accounted for ≤0.2 Fe(III)
per Glx2 molecule, suggesting that the majority of iron in the samples was present as Fe(II). A small feature at
3600 G (360 mT) suggested the possibility of an Fe(III)Fe(II) center, as in Glx2−5 (34), in a small proportion of the
molecules (Figure 3C). This was the only evidence for bona fide binding of Fe(III) to Glx2. The spectrum also
revealed a complex pattern of lines in the geff = 2 region that, from comparison with a standard Mn(II) signal,
suggested trace amounts of Mn(II), likely adventitiously bound.

Figure 5. EPR spectra of human Glx2 analogues (A) Glx2-LB and (B) Glx2-LB+1.5Zn+1.5 Fe. Trace C shows the g ∼
2 region of trace B expanded (thin line). Overlaid are a spectrum of Mn(II) in modeling wax (thick line) and a
signal from an Fe(III)Fe(II) center in Glx2−1 from Arabidopsis thaliana (thick line with circular markers). A signal
due to Cu(II) in the spectrometer cavity was subtracted from the experimental traces of human glyoxylase, and
imperfect subtraction is likely responsible for the poor correlation of the Mn(II) reference signal with the
glyoxylase signal in the g ∼ 2.01 region [3100−3200 G; this is where the intense g⊥ feature of Cu(II) is observed].
Spectra were recorded at a microwave power of 2 mW, 10 K, and a magnetic field modulation of 12 G (1.2 mT)
at 100 kHz.
EPR spectra of Glx2-Comin indicated that only ∼25% of the Co(II) in Glx2 was EPR-visible. The EPR spectrum itself,
recorded under nonsaturating conditions, was complex (Figure 6A). Individual species were deconvoluted by
preferential saturation of spectral components and by the collection and analysis of spectra recorded under
rapid passage conditions, in the presence of three distinct Co(II) species. The EPR spectrum recorded under
partially saturating conditions (Figure 6B) indicated that the derivative feature at 2040 G is not associated with
either the large absorption-shaped component at 1110 G or the derivative feature at 2660 G. Comparison of two
rapid-passage spectra recorded at different microwave powers (Figure 6C,D) indicated that the derivative
feature at 2660 G was associated with the broad absorption “tail” centered around 4000 G, and likely with some
absorption in the 800−1600 G range. Subtraction of appropriate amounts of Figure 6D from Figure 6C yielded an
apparently single-component axial signal that was readily simulated as an MS = ±1/2 species with an E/D of 0.1.
The experimental data, therefore, clearly identified that three distinct species contributed to the spectrum and
provided a full set of parameters for one of them. Using the axial species, the two associated features at 2660
and 4000 G from Figure 6D, and the distinct feature at 2040 G from Figure 6B as a basis for three species, the

experimental spectrum recorded under nonsaturating conditions was best simulated using the parameters
described in the legend of Figure 6. The simulations indicate that two of the species are likely five-coordinate
and the third is either five- or six-coordinate. It is of note that for one of the species, that of Figure 6B,
the greal values are unusually high for Co(II) in a metalloprotein, though not excessively so. Our assignment
to MS = ±1/2, and five-coordinate geometry, is based on comparison of the resultant greal values of 2.9, 2.9, and
3.0 with those returned by assuming the alternative MS = ±3/2 manifold, and hence distorted tetrahedral
geometry, of 3.4, 3.4, and 3.0, respectively. These latter values would be unprecedented for Co(II) in an
environment of the types found in the Glx2 active site.

Figure 6. EPR spectra of human Glx2 containing Co(II). (A) Experimental EPR spectrum of 1.7 mM Glx2 incubated
with 1.7 mM Co(II), recorded at 12 K and 0.8 mW. The doubly integrated intensity of the spectrum corresponded
to 0.4 mM Co(II). A simulated spectrum is overlaid; the simulated spectrum was generated by adding 0.21, 0.44,
and 0.35 fractional spin equivalent of computed spectra B, D, and E, respectively. (B), Experimental spectrum
recorded at 7.6 K and 100 mW and a computed spectrum with the following spin Hamiltonian
parameters: S = 3/2, MS = 1/2 (E ≫ gβSH), g∥ = 3.0, g⊥ = 2.9, and E/D = 0.28. (C) Rapid-passage δχ′′/δH EPR
spectrum recorded at 7.6 K and 100 mW. The experimental pseudoabsorption spectrum was collected with
second-harmonic out-of-phase modulation-phase-sensitive detection. The derivative spectrum shown was
generated by differentiating the experimental spectrum, applying 20 G pseudomodulation. (D) Rapid-passage
δχ′′/δH EPR spectrum recorded at 7.6 K and 10 mW. A computed spectrum is overlaid, with the following
parameters: S = 3/2, MS = 1/2 (E ≫ gβSH), g∥ = 2.15, g⊥ = 2.3, and E/D = 0.29. (E) Difference spectrum generated
by subtraction of a fraction of the experimental spectrum D from spectrum C and an overlaid computed
spectrum with the following parameters: S = 3/2, MS = 1/2 (E ≫ gβSH), g∥ = 2.9, g⊥ = 2.6, and E/D = 0.10. All
spectra were recorded with a magnetic field modulation of 12 G at 100 kHz.

Discussion
The metallo-β-lactamase fold consists of an αβ/βα sandwich motif, made up of a core unit of two β-sheets
surrounded by solvent-exposed helices (41, 42). Members of this superfamily contain a conserved HXHXD motif
that has been shown to bind Zn(II), Fe, and Mn. There are several enzymes in the metallo-β-lactamase fold
family, including metallo-β-lactamases, glyoxalase II, lactonase, rubredoxin:oxygen oxidoreductase (ROO),
arylsulfatase, phosphodiesterase, and tRNA maturase (50). Most of the members of the metallo-β-lactamase
superfamily (metallo-β-lactamases, tRNA maturase, phosphodiesterase, arylsulfatase, and lactonase) appear to
contain dinuclear Zn(II) centers. On the other hand, rubredoxin:oxygen oxidoreductase (ROO) appears to contain
a dinuclear iron center (51). Glx2 from E. coli was recently reported to contain a dinuclear Zn(II) center (35),
while plant mitochondrial Glx2 (Glx2−5) has been shown to contain a FeZn center (34). Interestingly, plant
cytoplasmic Glx2 (48, 49) and Glx2 from Salmonella typhimurium(39) can exist with a number of possible metal
centers, including dinuclear Fe, FeZn, MnZn, and presumably dinuclear Zn(II). On the basis of a crystal structure,
human Glx2 was reported to contain a dinuclear Zn(II) center, although the enzyme used for the crystallization
studies contained 1.5 equiv of Zn(II) and 0.7 equiv of Fe (40).
To more clearly define the metal binding properties of human Glx2, the protein was overexpressed in either LB
or minimum medium containing different metal ions. Human Glx2 overexpressed in LB medium bound roughly
equal, albeit substoichiometric, amounts of Zn(II) and Fe and exhibited a kcat of 570 s−1 and a very large Km value
of 660 μM (Table 1). Addition of Zn(II) and Fe to this enzyme followed by dialysis resulted in an enzyme (Glx2LB+1.5Zn+1.5Fe) that bound 1.2 ± 0.1 equiv of Zn(II) and 0.9 ± 0.1 equiv of Fe and exhibited an ∼20%
higher kcat and a similar Km (within error) value. The similar Km values suggest a common active species, yet a 2fold increase in metal content did not correspond to a 2-fold increase in kcat. This result is most likely due to the
as yet unexplained drop in activity when Glx2 samples are dialyzed (43, 52). There were also drops in kcat when
Glx2-Znmin was incubated with Zn(II) or Fe, followed by dialysis (Table 1).
The large Km values exhibited by human Glx2 samples prepared from LB medium were not observed for any of
the Glx2 analogues prepared from minimal medium (Table 1). This result suggests that the samples prepared in
LB contain a competitive inhibitor, perhaps a peptide from the LB medium. The presence of a competitive
inhibitor in the enzymes cultured in LB is supported by the stopped-flow studies that exhibit a lower activity for
Glx2-LB [less Zn(II)] and a similar activity for Glx2-LB+1.5Zn+1.5Fe analogues as compared to the Glx2 samples
prepared in minimal medium (Figure 2). The 1H NMR spectrum of Glx2-LB+1.5Zn+1.5Fe did not reveal any
unassigned peaks (Figure 3), suggesting that a peptide does not bind directly to the Fe(II) center. However, it is
possible that resonances from protons on a metal-bound peptide may not shift to downfield positions greater
than 30 ppm. In addition, the crystal structure of human Glx2 identified a number of active site residues that
interact with groups on glutathione (40), so the binding of a peptide to the metal may not be required for a
Glx2−peptide complex to form. MALDI-TOF mass spectrometry was used to compare multiple Glx2 samples
prepared in LB and minimal medium in an effort to identify a bound competitive inhibitor; however, no
differences in the masses of the different GLX2 analogues were identified. It is possible that the ionization
process coupled with the acidic matrix used in the MALDI technique resulted in the loss of the inhibitor.
In an effort to obtain human Glx2 containing only one metal ion, the enzyme was overexpressed in minimal
medium containing either Zn(II) or Fe(II). Glx2 overexpressed in minimal medium containing Zn(II) (Glx2-Znmin)
was shown to bind 1.1 ± 0.2 equiv of Zn(II) and no detectable Fe or Mn (Table 1). When Glx2-Znmin was incubated
with a 3-fold excess of Zn(II) and unbound Zn(II) was removed by dialysis, the resulting enzyme contained 0.9 ±
0.2 equiv of Zn(II). It is unlikely that the samples of Glx2-Znmin contain a mixture of ZnZn-Glx2 and apo-Glx2, since
we are unable to prepare an analogue of Glx2 containing 2 equiv of Zn(II) by adding Zn(II) to the sample. This
result is in contrast to the crystallographic conclusion that human Glx2 contains a dinuclear Zn(II) metal
center (40). With regard to iron in Glx2, both NMR and EPR indicated that iron in the iron-containing forms of

Glx2 was largely in the Fe(II) state. However, sufficient iron (≈ 20%) was present as Fe(III) to provide for an easily
observed EPR signal. Almost all of the Fe(III), however, was present as mononuclear Fe(III), and only a very small
signal that was suggestive of an Fe(III)Fe(II) center was observed. These data argue against any significant
proportion of di-iron Glx2. On the other hand, human Glx2 can bind two metal ions, and metal analyses and
spectroscopic studies suggest that Zn(II) binds in the consensus Zn1 site, while Ni(II), Co(II), and Fe(II) can bind in
the consensus Zn2 site. The formation of mixed-metal analogues is not surprising since mixed-metal analogues of
several metallo-β-lactamases have been reported (53-55). However, a surprising result is that a CoCo analogue
of human Glx2 can be prepared (Figure 3), while the biophysically and biochemically similar dinuclear Zn(II)
analogue cannot be prepared (see metal analysis data above). Given the bioavailability of the metal ions
tested (56), we hypothesize that human Glx2 contains a Zn(II)Fe(II) center in vivo. Unlike Arabidopsis Glx2−2 (49,
57), dinuclear Fe- or Zn(II)-containing analogues of human Glx2 cannot be prepared.
The steady-state kinetic studies on Glx2 samples prepared in minimal medium revealed some surprising results
with respect to metal content and activity. Glx2-Znmin, which contains ∼1 equiv of Zn(II), is the most active Zn(II)containing form of these analogues (Table 1), and the presence of Zn(II) or Fe(II) in the assay buffer does not
greatly affect the activity of the enzyme. This result demonstrates that a dinuclear metal center is not required
for the full catalytic activity of human Glx2 and that the second metal ion does not play a large role in catalysis.
The steady-state kinetic data did reveal that Glx2-Znmin, which was incubated with 3 equiv of Zn(II) or Fe(II),
exhibited similar albeit lower activities. This lower activity is probably due to the dilute (low nanomolar) enzyme
being somewhat unstable after dialysis. At the higher concentrations used in the stopped-flow studies, the Glx2Znmin+Zn and Glx2-Znmin+Fe analogues exhibited rates similar to that of Glx2-Znmin (Figure 2). The steady-state
and stopped-flow kinetic data for the Glx2-Znmin samples after incubation with Zn(II) or Fe(II) and dialysis show
that Fe has little or no effect on the activity of the enzyme. These data clearly show that human Glx2 is active
when there is a mononuclear Zn(II) bound to the enzyme, presumably in the Zn1 site. This result is important for
the rational design of inhibitors that target the metal binding site.
The most active form of human Glx2 is Glx2-Comin (Table 1 and Figure 2). NMR studies show that Co(II) binds to
both metal binding sites in this analogue (Figure 3). EPR spectra of Glx2-Comin revealed the presence of three
distinct Co(II) species, two rhombic and one axial. The exhibition of both an axial and a rhombic signal from a
single Co(II) binding site has been observed in a number of instances and, in some cases, has been shown to be
due to the different effects of water and hydroxyl ligands, in a pH-dependent equilibrium, on EPR strain
parameters (58). However, the presence of two highly rhombic species, and three species overall, indicates at
least two Co(II) binding sites, and the spin Hamiltonian parameters indicate five- or six-fold coordination in each
case. These data are entirely in accord with the NMR results, showing binding to both Zn1 and Zn2 sites, and with
the five- or six-fold coordination indicated by the electronic absorption spectrum. The Co(II) EPR signals
accounted for only ∼25% of the total Co(II) and corresponded to a population of Glx2 in which either the Zn1 or
Zn2 site was occupied. Most of the Co(II) in Glx2, then, is likely present in a dinuclear site that is EPR-silent due to
antiferromagnetic coupling. This coupling need only be very weak, on the order of a wavenumber, to preclude
observation of an EPR signal. When 1 equiv of Zn(II) is added to this enzyme, Zn(II) presumably displaces Co(II)
from the Zn1 site, and the resulting ZnCo analogue exhibits activity similar to that of Glx2-Znmin. These results
suggest that the most active analogue of human Glx2 has Co(II) in the Zn1 site and that the metal ion in the
Zn2 site plays little role in catalysis. We have attempted to prepare a CoCo analogue of human Glx2 by adding
Co(II) to Glx2-Comin; however, the enzyme precipitates upon addition of Co(II). It is not clear why Glx2-Comin is
more active than the corresponding Glx2-Znmin or ZnCo analogues; however, the greater Lewis acidity of Co(II) as
compared to that of Zn(II) may explain some of the differences (59). Co(II)-substituted liver alcohol
dehydrogenase is 140% more active than the corresponding Zn(II)-containing enzyme (59). In spite of greater
activity, the relatively lower bioavailability of Co(II), as compared to that of Zn(II) or Fe, strongly suggests that
human Glx2 is not a Co(II)-containing enzyme.

The results present here demonstrate that human Glx2 is active as a mononuclear Zn(II)-containing enzyme and
that Zn(II) binds preferentially to the consensus Zn1 site. This finding is similar to a recent study that reported
that metallo-β-lactamase L1 is active as a mononuclear Zn(II) enzyme when Zn(II) is bound in the Zn1 site (53).
The metal content of the active forms of other enzymes belonging to the metallo-β-lactamase superfamily is not
clear. Unlike the other enzymes in this superfamily, the metal ion in the Zn2 site does not appear to play a
significant role in human Glx2. Nonetheless, given the bioavailability of Zn(II) and Fe in cells (56), we predict that
human Glx2 contains a Zn(II)Fe(II) metal binding site in vivo and not a Zn(II)Zn(II) site as previously reported (40).
It has been proposed that the enzymes in the metallo-β-lactamase superfamily arose due to a gene duplication
event (50), and the presence of a dinuclear metal binding site may offer some of the enzymes increased activity.
Since Glx2 appears to be a critical enzyme involved in the cellular detoxification of 2-oxoaldehydes (1), it may
have evolved to be active with only one metal ion, so that the enzyme is active in the presence of low Zn(II)
concentrations. The ability to utilize only the single, non-redox active Zn(II) site for catalysis would better
position the enzyme to react with the oxidizing substrates.
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